Phase 4
N=17
Use of Topical Tranexamic Acid and Bacitracin in Dialysis Patients
Arteriovenous Fistula
Bottom Line
View on ClinicalTrials.gov: NCT02106962 ↗Enrolled (actual)
17
Serious AEs
0.0%
Results posted
Sep 2017
Primary outcome: Primary: Clotting TIme — 6; 8 minutes
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- Topical Tranexamic Acid 5% with bacitracin (Drug); Topical Tranexamic Acid 25% with bacitracin (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- California Institute of Renal Research
- Primary completion
- Aug 2014
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Clotting TIme |
6; 8 | — |
| SECONDARY Local Infection |
0; 0 | — |
Summary
This study will investigate how the use of Tranexamic acid and Bacitracin applied to the bleeding site after the hemodialysis fistula needle is removed will affect Time to Clot and Infection Rate
Eligibility Criteria
Inclusion Criteria
- Dialysis patients with fistulas (native arterio-venous)
Exclusion Criteria
- Previous sensitivity to or adverse reaction to Tranexamic acid or Bacitracin.
- Active infection.
- Stenosis of fistula.
Data sourced from ClinicalTrials.gov (NCT02106962). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.